发明授权
US08435970B2 Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
失效
1-环丙基-3- [3-(5-吗啉-4-基甲基-1H-苯并咪唑-2-基)-1H-吡唑-4-基] - 脲的药物组合
- 专利标题: Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
- 专利标题(中): 1-环丙基-3- [3-(5-吗啉-4-基甲基-1H-苯并咪唑-2-基)-1H-吡唑-4-基] - 脲的药物组合
-
申请号: US12306479申请日: 2007-06-29
-
公开(公告)号: US08435970B2公开(公告)日: 2013-05-07
- 发明人: Jayne Elizabeth Curry , Neil James Gallagher , John Francis Lyons , Neil Thomas Thompson
- 申请人: Jayne Elizabeth Curry , Neil James Gallagher , John Francis Lyons , Neil Thomas Thompson
- 申请人地址: GB Cambridge
- 专利权人: Astex Therapeutics Limited
- 当前专利权人: Astex Therapeutics Limited
- 当前专利权人地址: GB Cambridge
- 代理机构: Heslin Rothenberg Farley & Mesiti P.C.
- 国际申请: PCT/GB2007/002447 WO 20070629
- 国际公布: WO2008/001115 WO 20080103
- 主分类号: A61K31/56
- IPC分类号: A61K31/56 ; A61K31/535 ; A61K31/52 ; A61K31/44 ; A61K31/445
摘要:
The invention provides combinations of an ancillary compound and a compound which is a salt of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea selected from the lactate and citrate salts and mixtures thereof. Also provided are crystalline forms of the salts, methods for making the salts and their uses in treating cancers. The invention further provides combinations of an ancillary compound and a compound of the formula (I) as defined in PCT/GB2004/002824 (WO 2005/002552) or a compound of the formula (I′) or a salt, solvate, tautomer or N-oxide thereof, wherein R1, E, A and M are as defined in the claims.
公开/授权文献
信息查询